Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

UCB and Biogen say their first phase 3 trial of systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, with a second planned.

Explore the BHEL Artisan Syllabus 2025, including exam pattern, post-wise syllabus, prep tips, and other details on this page ...

Here’s WAVE News meteorologist Carson Meredith with your forecast. Download the weather app from the WAVE News Storm Tracking Team LOUISVILLE, Ky. (WAVE) - An ALERT DAY is in place this evening as ...

Scattered thunderstorms are possible this evening with an uptick expected after midnight into early Saturday.